Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Finished

GBM Neuro Snooper Preclinical in vivo validation of a glioblastoma neuro snooper electrical device

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 November 2023 to 30 April 2025
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101137960

What the project is doing

In the project's own words, from its summary on CORDIS.

Median survival for people that are diagnosed with glioblastoma (GBM) is only 15 months. Chemoradiotherapy and targeted therapies still fail to combat peritumoral relapse after tumour removal. Preventing peritumoral brain invasion is the main target to cure GBM. Our project aims to validate a proof-of concept for a new medical device (MD) ‘GBM Neuro Snooper’ in GBM animal models, a required step before initiating a clinical trial (Technology Readiness Level from 2/3 to 4).

This MD will allow to define an in-situ electrophysiology profile of patients with GBM, after the tumor resection, to access a new mechanistic understanding in the brain tumour field as well as, new strategies for patient stratification and treatment. Already existing MDs with electrode wires are either very stiff or with a millimetric dimension. The ERC work will lead to a first generic, miniaturised prototype implant with moderate invasiveness and which design was validated in connection with neurosurgeons for the GBM application, validation of its Freedom to Operate in the context of continuous IP landscaping and the creation of an exploitation plan.

In a long-term perspective, it will help characterise hyperexcitability in brain diseases such as tumors, but also epilepsy or the Alzheimer Disease. We will also investigate the effect of stimulation of the peritumoral tissue and the correlation with the recorded signals as a new electro-theragnostic strategy. We will address the ethics and social dimension of using such a MD and our exploitation plan will include the protection of intellectual property, business strategy and the preparation of a clinical trial after project completion.

The project will be performed by a dedicated team that includes significant expertise in technical development, preclinical validation of devices, surgery, and knowledge transfer.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI